(Q34293096)

1 August 2017

1 reference

title

Vaccines for colorectal cancer (English)

1 reference

1 August 2017

1 reference

1 reference

Zeh HJ

1

1 reference

1 August 2017

Stavely-O'Carroll K

series ordinal

2

1 reference

1 August 2017

Choti MA

series ordinal

3

1 reference

1 August 2017

publication date

1 July 2001

1 reference

Trends in Molecular Medicine

1 August 2017

published in

1 reference

1 August 2017

volume

7

1 reference

1 August 2017

issue

7

1 reference

1 August 2017

page(s)

307-313

1 reference

1 August 2017

cites work

Cancer statistics, 2000.

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2801%2901992-X

7 January 2021

Third Keystone Symposium on Cellular Immunology and the Immunotherapy of Cancer. Introduction

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2801%2901992-X

7 January 2021

Development of cancer immunotherapies based on identification of the genes encoding cancer regression antigens

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2801%2901992-X

7 January 2021

Tumor recognition by the cellular immune system: new aspects of tumor immunology.

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2801%2901992-X

7 January 2021

Class I MHC molecules: assembly and antigen presentation

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2801%2901992-X

7 January 2021

From TCR Engagement to T Cell Activation

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2801%2901992-X

7 January 2021

The role of B7 costimulation in T-cell immunity.

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2801%2901992-X

7 January 2021

https://api.crossref.org/works/10.1016%2FS1471-4914%2801%2901992-X

1 reference

7 January 2021

CD27/CD70 interactions regulate T dependent B cell differentiation

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2801%2901992-X

7 January 2021

T-cell costimulation via CD28-CD80/CD86 and CD40-CD40 ligand interactions

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2801%2901992-X

7 January 2021

An innate sense of danger

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2801%2901992-X

7 January 2021

Dendritic cells in cancer immunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2801%2901992-X

7 January 2021

Adjuvant active specific immunotherapy for human colorectal cancer: 6.5-year median follow-up of a phase III prospectively randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2801%2901992-X

7 January 2021

Adjuvant active specific immunotherapy for stage II and III colon cancer with an autologous tumor cell vaccine: Eastern Cooperative Oncology Group Study E5283.

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2801%2901992-X

7 January 2021

Active specific immunotherapy for stage II and stage III human colon cancer: a randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2801%2901992-X

7 January 2021

Prospectively randomized trial of adjuvant active-specific immunotherapy for human colorectal cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2801%2901992-X

7 January 2021

Interaction of dendritic cells with mycobacteria: where the action starts

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2801%2901992-X

7 January 2021

Paracrine cytokine adjuvants in cancer immunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2801%2901992-X

7 January 2021

Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2801%2901992-X

7 January 2021

Phase I study of non-replicating autologous tumor cell injections using cells prepared with or without GM-CSF gene transduction in patients with metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2801%2901992-X

7 January 2021

Novel allogeneic granulocyte-macrophage colony-stimulating factor-secreting tumor vaccine for pancreatic cancer: a phase I trial of safety and immune activation

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2801%2901992-X

7 January 2021

A phase I clinical trial of lethally irradiated allogeneic pancreatic tumor cells transfected with the GM-CSF gene for the treatment of pancreatic adenocarcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2801%2901992-X

7 January 2021

Treatment of liver metastases from colon carcinoma with autologous tumor vaccine expressing granulocyte-macrophage colony-stimulating factor

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2801%2901992-X

7 January 2021

Successful culture and selection of cytokine gene-modified human dermal fibroblasts for the biologic therapy of patients with cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2801%2901992-X

7 January 2021

Developing recombinant and synthetic vaccines for the treatment of melanoma.

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2801%2901992-X

7 January 2021

Antitumor Activity and Immune Responses Induced by a Recombinant Carcinoembryonic Antigen-Vaccinia Virus Vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2801%2901992-X

7 January 2021

Antitumor immunization with a minimal peptide epitope (G9-209-2M) leads to a functionally heterogeneous CTL response

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2801%2901992-X

7 January 2021

Peptide-pulsed dendritic cells induce antigen-specific CTL-mediated protective tumor immunity

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2801%2901992-X

7 January 2021

DNA vaccines targeting dendritic cells for the immunotherapy of cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2801%2901992-X

7 January 2021

The combined effect against colon-26 cells of heat treatment and immunization with heat treated colon-26 tumour cell extract

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2801%2901992-X

7 January 2021

Generation of Human Cytotoxic T Cells Specific for Human Carcinoembryonic Antigen Epitopes From Patients Immunized With Recombinant Vaccinia-CEA Vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2801%2901992-X

7 January 2021

Phase I study in advanced cancer patients of a diversified prime-and-boost vaccination protocol using recombinant vaccinia virus and recombinant nonreplicating avipox virus to elicit anti-carcinoembryonic antigen immune responses

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2801%2901992-X

7 January 2021

A phase I trial of a synthetic mucin peptide vaccine. Induction of specific immune reactivity in patients with adenocarcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2801%2901992-X

7 January 2021

New treatment options for patients with melanoma: review of melanoma-derived T-cell epitope-based peptide vaccines.

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2801%2901992-X

7 January 2021

Clonal expansion of Melan A-specific cytotoxic T lymphocytes in a melanoma patient responding to continued immunization with melanoma-associated peptides

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2801%2901992-X

7 January 2021

Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2801%2901992-X

7 January 2021

Cytotoxic CD4+ and CD8+ T lymphocytes, generated by mutant p21-ras (12Val) peptide vaccination of a patient, recognize 12Val-dependent nested epitopes present within the vaccine peptide and kill autologous tumour cells carrying this mutation

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2801%2901992-X

7 January 2021

Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2801%2901992-X

7 January 2021

Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2801%2901992-X

7 January 2021

Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2801%2901992-X

7 January 2021

Clinical and immune responses in resected colon cancer patients treated with anti-idiotype monoclonal antibody vaccine that mimics the carcinoembryonic antigen

1 reference

https://api.crossref.org/works/10.1016%2FS1471-4914%2801%2901992-X

7 January 2021

10.1016/S1471-4914(01)01992-X

Identifiers

DOI

1 reference

1 August 2017

1 reference